CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease

S0120 G.E.M.S.: genomics encounters MGUS and SMM

(2014) A. Dispenzieri   BLOOD

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma

(2013) S. Z. Usmani et al.   BLOOD

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)

(2013) M. V. Dhodapkar et al.   BLOOD

Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS

(2012) J A Katzmann et al.   LEUKEMIA

Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease

(2011) J. A. Fowler et al.   BLOOD

Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1  levels in patients with MGUS

(2011) A. C. Ng et al.   BLOOD

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies

(2011) N. Korde et al.   BLOOD

CCN1/CYR61: the very model of a modern matricellular protein

(2011) Lester F. Lau   CELLULAR AND MOLECULAR LIFE SCIENCES

Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management

(2011) Sigurdur Y Kristinsson et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Sclerostin binds and regulates the activity of cysteine-rich protein 61

(2010) Theodore A. Craig et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Expression of multiple myeloma associated markers in bone marrow spicules using a novel immunohistochemical technique

(2010) M Santra et al.   BIOTECHNIC & HISTOCHEMISTRY

CYR61 Regulates BMP-2-dependent Osteoblast Differentiation through the αvβ3Integrin/Integrin-linked Kinase/ERK Pathway

(2010) Jen-Liang Su et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Consequences of Daily Administered Parathyroid Hormone on Myeloma Growth, Bone Disease, and Molecular Profiling of Whole Myelomatous Bone

(2010) Angela Pennisi et al.   PLoS One

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

(2010) S. Vallet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma

(2010) Brendan M Weiss et al.   Expert Review of Hematology

The significance of monoclonal gammopathy of undetermined significance

(2009) R. A. Kyle et al.   HAEMATOLOGICA

Fas-Mediated Apoptosis Is Regulated by the Extracellular Matrix Protein CCN1 (CYR61) In Vitro and In Vivo

(2009) V. Juric et al.   MOLECULAR AND CELLULAR BIOLOGY

High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone

(2008) F. Zhan et al.   BLOOD

Role of decorin in the antimyeloma effects of osteoblasts

(2008) X. Li et al.   BLOOD

Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth

(2008) Y.-W. Qiang et al.   BLOOD

Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma

(2008) Y.-W. Qiang et al.   BLOOD

Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma

(2007) Ya-Wei Qiang et al.   BONE